A role for the endocannabinoid system in hepatic steatosis Sistema endocanabinoide y desarrollo de esteatosis hepática
Author
dc.contributor.author
Valenzuela, Carina
Author
dc.contributor.author
Castillo, Valeska
Author
dc.contributor.author
Ronco Macchiavello, Ana María
Author
dc.contributor.author
Aguirre, Carolina
Author
dc.contributor.author
Hirsch Birn, Sandra
Author
dc.contributor.author
Llanos Silva, Miguel
Admission date
dc.date.accessioned
2019-03-15T16:06:48Z
Available date
dc.date.available
2019-03-15T16:06:48Z
Publication date
dc.date.issued
2014
Cita de ítem
dc.identifier.citation
Revista Medica de Chile, Volumen 142, Issue 3, 2018, Pages 353-360
Identifier
dc.identifier.issn
07176163
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.other
10.4067/S0034-98872014000300010
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/166206
Abstract
dc.description.abstract
The endocannabinoid system (SEC) is an important modulator of several metabolic functions. This system is composed by cannabinoid receptors type 1 and 2 (RCB1 and RCB2), their endogenous ligands, known as endocannabinoids, and the enzymes involved in their synthesis and degradation. A deregulated SEC originates metabolic alterations in several tissues, resulting in the typical manifestations of the metabolic syndrome. Liver steatosis of different origins constitutes a physiopathological condition where an altered hepatic SEC is observed. In this condition, there is an increased expression of RCB1 and/or higher endocannabinoid levels in different hepatic cells, which may exert an autocrine/ paracrine hyperstimulation of RCB1/RCB2. Activation of RCB1 stimulate the expression of several hepatocyte lipogenic factors, thus leading to increased de novo fatty acids synthesis and consequently to an abnormal accumulation of triglycerides. The effect of RCB2 activity on hepatic function is still